ACRX
AcelRx Pharmaceuticals, Inc. [ACRX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ACRX Stock Summary
In the News
ACRX Financial details
ACRX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.58 | 1.27 | 0.47 | 0.24 | 0 | |
| Net income per share | -13.45 | -9.47 | -5.86 | 6.45 | 0 | |
| Operating cash flow per share | -12.93 | -9.03 | -5.01 | -3.82 | 0 | |
| Free cash flow per share | -13.8 | -9.47 | -5.31 | -3.87 | 0 | |
| Cash per share | 16.7 | 10.06 | 8.62 | 2.13 | 0 | |
| Book value per share | -10.46 | -13.08 | -5.99 | 2.95 | 0 | |
| Tangible book value per share | -10.46 | -13.08 | -5.99 | 1.75 | 0 | |
| Share holders equity per share | -10.46 | -13.08 | -5.99 | 2.95 | 0 | |
| Interest debt per share | 7.82 | 6.78 | 3.49 | 1.56 | 0 | |
| Market cap | 167.08M | 105.72M | 67.12M | 16.74M | 10.48B | |
| Enterprise value | 182.15M | 104.04M | 73.08M | 11.89M | 10.48B | |
| P/E ratio | -3.14 | -2.62 | -1.91 | 0.35 | -1.02K | |
| Price to sales ratio | 72.99 | 19.52 | 23.82 | 9.45 | 16.1K | |
| POCF ratio | -3.26 | -2.75 | -2.24 | -0.59 | -599.35 | |
| PFCF ratio | -3.06 | -2.62 | -2.11 | -0.58 | -595.94 | |
| P/B Ratio | -4.03 | -1.9 | -1.87 | 0.77 | 743.27 | |
| PTB ratio | -4.03 | -1.9 | -1.87 | 0.77 | 743.27 | |
| EV to sales | 79.58 | 19.21 | 25.93 | 6.71 | 16.1K | |
| Enterprise value over EBITDA | -3.5 | -2.81 | -2.37 | -0.39 | -620.41 | |
| EV to operating cash flow | -3.56 | -2.7 | -2.44 | -0.42 | -599.02 | |
| EV to free cash flow | -3.33 | -2.58 | -2.3 | -0.41 | -595.62 | |
| Earnings yield | -0.32 | -0.38 | -0.52 | 2.85 | 0 | |
| Free cash flow yield | -0.33 | -0.38 | -0.47 | -1.71 | 0 | |
| Debt to equity | -0.72 | -0.46 | -0.52 | 0.48 | 0 | |
| Debt to assets | 0.33 | 0.39 | 0.24 | 0.22 | 0 | |
| Net debt to EBITDA | -0.29 | 0.05 | -0.19 | 0.16 | 0.34 | |
| Current ratio | 5.27 | 2.66 | 3 | 1.78 | 2.56 | |
| Interest coverage | -45.25 | -12.39 | -15.7 | -31.77 | 126.04 | |
| Income quality | 0.96 | 0.95 | 0.85 | -0.59 | 0.95 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | -0.01 | 0 | 0 | |
| Sales general and administrative to revenue | 19.19 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 2.04 | 0.74 | 1.45 | 2.93 | 8.52 | |
| Intangibles to total assets | 0 | 0 | 0 | 0.19 | 0 | |
| Capex to operating cash flow | 0.07 | 0.05 | 0.06 | 0.01 | 0.01 | |
| Capex to revenue | -1.52 | -0.34 | -0.65 | -0.21 | -0.15 | |
| Capex to depreciation | -2.08 | -1 | -0.93 | -0.22 | -0.32 | |
| Stock based compensation to revenue | 2.21 | 0.82 | 1.64 | 1.63 | 2.66 | |
| Graham number | 56.26 | 52.79 | 28.09 | 20.67 | 0 | |
| ROIC | 7.69 | 1.55 | 2.89 | -0.99 | -1.2 | |
| Return on tangible assets | -0.58 | -0.61 | -0.45 | 1.24 | -0.5 | |
| Graham Net | -16.32 | -18.27 | -10.26 | -1.23 | 0 | |
| Working capital | 58.08M | 29.2M | 36.98M | 10.8M | 7.04M | |
| Tangible asset value | -41.42M | -55.75M | -35.89M | 13M | 14.11M | |
| Net current asset value | -61.09M | -75.22M | -58.3M | -1.11M | 5.27M | |
| Invested capital | -0.72 | -0.46 | -0.52 | 0.48 | 0 | |
| Average receivables | 460.5K | 577.5K | 397.5K | 234.5K | 154.5K | |
| Average payables | 1.9M | 2.23M | 2.43M | 2.08M | 1.69M | |
| Average inventory | 2.07M | 2.46M | 1.37M | 1.14M | 589K | |
| Days sales outstanding | 82.92 | 42.79 | 20.72 | 63.68 | 0 | |
| Days payables outstanding | 92.24 | 165.62 | 206.28 | 287.38 | 0 | |
| Days of inventory on hand | 176.71 | 98.39 | 108.05 | 165.95 | 0 | |
| Receivables turnover | 4.4 | 8.53 | 17.61 | 5.73 | 0 | |
| Payables turnover | 3.96 | 2.2 | 1.77 | 1.27 | 0 | |
| Inventory turnover | 2.07 | 3.71 | 3.38 | 2.2 | 0 | |
| ROE | 1.29 | 0.72 | 0.98 | 2.19 | -0.73 | |
| Capex per share | -0.88 | -0.44 | -0.3 | -0.05 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.07 | 0.03 | 0 | 0.02 | 0.01 | |
| Net income per share | -0.91 | -1.01 | 0.49 | -0.4 | -0.08 | |
| Operating cash flow per share | -0.71 | -0.73 | -0.48 | -0.49 | -0.18 | |
| Free cash flow per share | -0.73 | -0.74 | -0.49 | -0.49 | -0.18 | |
| Cash per share | 2.16 | 2.13 | 1.23 | 0.68 | 0.8 | |
| Book value per share | 3.73 | 2.95 | 1.31 | 0.95 | 1.09 | |
| Tangible book value per share | 2.54 | 1.75 | 0.5 | 0.15 | 0.57 | |
| Share holders equity per share | 3.73 | 2.95 | 1.31 | 0.95 | 1.09 | |
| Interest debt per share | 1.72 | 1.43 | 0.32 | 0.04 | 0 | |
| Market cap | 30.98M | 16.74M | 7.19M | 12.13M | 9.72M | |
| Enterprise value | 30.73M | 11.89M | -2.79M | 4.72M | -3.67M | |
| P/E ratio | -1.15 | -0.56 | 0.34 | -0.69 | -1.79 | |
| Price to sales ratio | 61.11 | 66.43 | 0 | 47.93 | 83.07 | |
| POCF ratio | -5.92 | -3.09 | -1.37 | -2.27 | -3.28 | |
| PFCF ratio | -5.74 | -3.07 | -1.34 | -2.27 | -3.28 | |
| P/B Ratio | 1.13 | 0.77 | 0.5 | 1.16 | 0.53 | |
| PTB ratio | 1.13 | 0.77 | 0.5 | 1.16 | 0.53 | |
| EV to sales | 60.61 | 47.17 | 0 | 18.64 | -31.36 | |
| Enterprise value over EBITDA | -5.06 | -1.64 | -6.28 | -1.2 | 2.59 | |
| EV to operating cash flow | -5.87 | -2.2 | 0.53 | -0.88 | 1.24 | |
| EV to free cash flow | -5.69 | -2.18 | 0.52 | -0.88 | 1.24 | |
| Earnings yield | -0.22 | -0.45 | 0.74 | -0.36 | -0.14 | |
| Free cash flow yield | -0.17 | -0.33 | -0.74 | -0.44 | -0.3 | |
| Debt to equity | 0.45 | 0.48 | 0.24 | 0 | 0 | |
| Debt to assets | 0.26 | 0.22 | 0.13 | 0 | 0 | |
| Net debt to EBITDA | 0.04 | 0.67 | -22.44 | 1.89 | 9.46 | |
| Current ratio | 1.57 | 1.78 | 1.83 | 2.09 | 4.04 | |
| Interest coverage | -26.85 | -39.33 | 1.54 | -8.7 | 0 | |
| Income quality | 0.78 | 0.72 | 0.64 | 1.22 | 2.18 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 2.58 | 4.07 | 0 | 6.13 | 10.07 | |
| Intangibles to total assets | 0.18 | 0.19 | 0.34 | 0.5 | 0.38 | |
| Capex to operating cash flow | 0.03 | 0.01 | 0.02 | 0 | 0 | |
| Capex to revenue | -0.31 | -0.19 | 0 | 0 | 0 | |
| Capex to depreciation | -0.37 | -0.14 | -0.38 | 0 | 0 | |
| Stock based compensation to revenue | 1.38 | 2.59 | 0 | 1.86 | 3.23 | |
| Graham number | 8.77 | 8.18 | 3.8 | 2.93 | 1.41 | |
| ROIC | -0.15 | -0.2 | 0.86 | -0.38 | -0.18 | |
| Return on tangible assets | -0.17 | -0.19 | 0.31 | -0.49 | -0.09 | |
| Graham Net | -0.55 | -1.23 | 0.19 | 0.01 | 0.5 | |
| Working capital | 8.89M | 10.8M | 7.89M | 4.62M | 10.85M | |
| Tangible asset value | 18.72M | 13M | 5.42M | 1.6M | 9.49M | |
| Net current asset value | 3.77M | -1.11M | 5.3M | 1.53M | 9.47M | |
| Invested capital | 0.45 | 0.48 | 0.24 | 0 | 0 | |
| Average receivables | 438K | 410.5K | 292.5K | 145.5K | 7.5K | |
| Average payables | 2.2M | 2.02M | 1.72M | 1.31M | 1.12M | |
| Average inventory | 887.5K | 1.03M | 1.15M | 564K | 5.5K | |
| Days sales outstanding | 90.89 | 110.36 | 0 | 5.34 | 0 | |
| Days payables outstanding | 316.82 | 507.18 | 120.17 | 70.28 | 0 | |
| Days of inventory on hand | 138.24 | 292.87 | 96.02 | 0.64 | 0 | |
| Receivables turnover | 0.99 | 0.82 | 0 | 16.87 | 0 | |
| Payables turnover | 0.28 | 0.18 | 0.75 | 1.28 | 0 | |
| Inventory turnover | 0.65 | 0.31 | 0.94 | 141.09 | 0 | |
| ROE | -0.25 | -0.34 | 0.37 | -0.42 | -0.07 | |
| Capex per share | -0.02 | -0.01 | -0.01 | 0 | 0 |
ACRX Frequently Asked Questions
What is AcelRx Pharmaceuticals, Inc. stock symbol ?
AcelRx Pharmaceuticals, Inc. is a US stock , located in Hayward of Ca and trading under the symbol ACRX
What is AcelRx Pharmaceuticals, Inc. stock quote today ?
AcelRx Pharmaceuticals, Inc. stock price is $0.922 today.
Is AcelRx Pharmaceuticals, Inc. stock public?
Yes, AcelRx Pharmaceuticals, Inc. is a publicly traded company.
Company Profile
- Volume Average 138.82K
- Market Capitalization 14.58M
- Employee 19
- CEO Mr. Vincent J. Angotti
- Headquarters Hayward,CA,US
- IPO Date 2011-02-11
-
Website
https://www.acelrx.com 
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.
